Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Cash from Financing Activities (2016 - 2025)

Aytu Biopharma (AYTU) has disclosed Cash from Financing Activities for 15 consecutive years, with -$6.3 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 126.92% to -$6.3 million in Q4 2025 year-over-year; TTM through Dec 2025 was $13.3 million, a 5408.76% increase, with the full-year FY2025 number at $15.4 million, up 1323.69% from a year prior.
  • Cash from Financing Activities was -$6.3 million for Q4 2025 at Aytu Biopharma, down from $2.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $13.6 million in Q3 2022 to a low of -$6.3 million in Q4 2025.
  • A 5-year average of $1.7 million and a median of $911000.0 in 2024 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: plummeted 2090.48% in 2024, then surged 1116.57% in 2025.
  • Aytu Biopharma's Cash from Financing Activities stood at $6.6 million in 2021, then crashed by 128.3% to -$1.9 million in 2022, then skyrocketed by 93.24% to -$126000.0 in 2023, then tumbled by 2090.48% to -$2.8 million in 2024, then plummeted by 126.92% to -$6.3 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Cash from Financing Activities are -$6.3 million (Q4 2025), $2.3 million (Q3 2025), and $13.0 million (Q2 2025).